Experimental therapies for neurodevelopmental genetic syndes

In July 2026, researchers reported that an AAV‑based gene‑replacement therapy restored the missing fragile X protein in mouse models, alleviating seizures, sensory hyperactivity, repetitive behavior, and EEG abnormalities. The study showed efficacy when treatment was given at developmental stages analogous to both early childhood and adulthood, suggesting a broad therapeutic window.

Later that month, a separate team demonstrated that the antioxidant N‑acetyl cysteine can mitigate the cellular consequences of a 22q11.2 deletion in mice. By reducing oxidative stress and improving mitochondrial health, the compound enabled neurons to form stronger synaptic connections despite the genetic loss. This approach leverages a bypass strategy rather than direct gene correction.

Together, the two studies illustrate a widening pre‑clinical focus on diverse molecular strategies—gene replacement and cellular stress modulation—to address a range of neurodevelopmental genetic disorders, expanding the potential therapeutic toolkit ahead of human trials.